Curexo Inc
Curexo Inc. engages in the development and sale of medical devices in Korea and internationally. Its products include ROBIN, a robot system that guides needle path induring CT-guided interventional procedure; Baidy, a medical device that assists labor by increasing intrauterine pressure which helps natural childbirth; artificial joint surgical robot; and Gait rehabilitation robot. The company als… Read more
Curexo Inc (060280) - Net Assets
Latest net assets as of September 2025: ₩94.30 Billion KRW
Based on the latest financial reports, Curexo Inc (060280) has net assets worth ₩94.30 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩103.65 Billion) and total liabilities (₩9.36 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩94.30 Billion |
| % of Total Assets | 90.97% |
| Annual Growth Rate | 6.84% |
| 5-Year Change | 108.46% |
| 10-Year Change | 178.68% |
| Growth Volatility | 52.59 |
Curexo Inc - Net Assets Trend (2006–2024)
This chart illustrates how Curexo Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Curexo Inc (2006–2024)
The table below shows the annual net assets of Curexo Inc from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩93.38 Billion | -7.02% |
| 2023-12-31 | ₩100.43 Billion | +22.95% |
| 2022-12-31 | ₩81.68 Billion | +90.39% |
| 2021-12-31 | ₩42.90 Billion | -4.23% |
| 2020-12-31 | ₩44.79 Billion | +1.85% |
| 2019-12-31 | ₩43.98 Billion | -37.20% |
| 2018-12-31 | ₩70.03 Billion | -0.94% |
| 2017-12-31 | ₩70.69 Billion | -3.27% |
| 2016-12-31 | ₩73.08 Billion | +118.10% |
| 2015-12-31 | ₩33.51 Billion | +140.36% |
| 2014-12-31 | ₩13.94 Billion | -60.27% |
| 2013-12-31 | ₩35.09 Billion | -29.09% |
| 2012-12-31 | ₩49.48 Billion | +52.74% |
| 2011-12-31 | ₩32.39 Billion | +38.77% |
| 2010-12-31 | ₩23.34 Billion | +16.28% |
| 2009-12-31 | ₩20.08 Billion | -44.29% |
| 2008-12-31 | ₩36.04 Billion | +27.48% |
| 2007-12-31 | ₩28.27 Billion | -0.40% |
| 2006-12-31 | ₩28.38 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Curexo Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14904955625000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩20.54 Billion | 22.00% |
| Other Components | ₩221.89 Billion | 237.61% |
| Total Equity | ₩93.38 Billion | 100.00% |
Curexo Inc Competitors by Market Cap
The table below lists competitors of Curexo Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NOCIL Limited
NSE:NOCIL
|
$152.64 Million |
|
EnTie Commercial Bank Ltd
TW:2849
|
$152.68 Million |
|
TMC the metals company Inc Warrants
NASDAQ:TMCWW
|
$152.69 Million |
|
ASTON MART.LA.UADR LS-001
F:A5S0
|
$152.83 Million |
|
North-Star International Co Ltd
TWO:8927
|
$152.61 Million |
|
Guangdong Nedfon Air System Co. Ltd.
SHE:301043
|
$152.61 Million |
|
Protec Co. Ltd
KQ:053610
|
$152.60 Million |
|
Korea District Heating Corp
KO:071320
|
$152.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Curexo Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 100,428,580,220 to 93,380,746,180, a change of -7,047,834,040 (-7.0%).
- Net loss of 8,757,927,990 reduced equity.
- Share repurchases of 1,270,524,400 reduced equity.
- New share issuances of 1,270,524,400 increased equity.
- Other factors increased equity by 1,710,093,950.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-8.76 Billion | -9.38% |
| Share Repurchases | ₩1.27 Billion | -1.36% |
| Share Issuances | ₩1.27 Billion | +1.36% |
| Other Changes | ₩1.71 Billion | +1.83% |
| Total Change | ₩- | -7.02% |
Book Value vs Market Value Analysis
This analysis compares Curexo Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.68x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 5.80x to 6.68x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2615.56 | ₩15170.00 | x |
| 2017-12-31 | ₩2327.43 | ₩15170.00 | x |
| 2018-12-31 | ₩2099.37 | ₩15170.00 | x |
| 2019-12-31 | ₩1318.45 | ₩15170.00 | x |
| 2020-12-31 | ₩1341.04 | ₩15170.00 | x |
| 2021-12-31 | ₩1282.60 | ₩15170.00 | x |
| 2022-12-31 | ₩2099.37 | ₩15170.00 | x |
| 2023-12-31 | ₩2452.11 | ₩15170.00 | x |
| 2024-12-31 | ₩2272.59 | ₩15170.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Curexo Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15.77%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.10x
- Recent ROE (-9.38%) is above the historical average (-19.86%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -34.51% | -53.75% | 0.47x | 1.36x | ₩-16.83 Billion |
| 2013 | -24.52% | -24.01% | 0.79x | 1.30x | ₩-10.51 Billion |
| 2014 | -56.84% | -41.55% | 0.65x | 2.11x | ₩-12.77 Billion |
| 2015 | -28.06% | -34.15% | 0.47x | 1.75x | ₩-12.75 Billion |
| 2016 | 33.05% | 80.34% | 0.38x | 1.07x | ₩16.84 Billion |
| 2017 | -23.89% | -50.43% | 0.44x | 1.07x | ₩-23.95 Billion |
| 2018 | -42.01% | -86.81% | 0.46x | 1.05x | ₩-36.42 Billion |
| 2019 | -58.93% | -75.37% | 0.73x | 1.07x | ₩-30.32 Billion |
| 2020 | 0.93% | 1.06% | 0.80x | 1.09x | ₩-4.06 Billion |
| 2021 | -5.46% | -5.47% | 0.70x | 1.43x | ₩-6.63 Billion |
| 2022 | -3.72% | -4.68% | 0.66x | 1.20x | ₩-11.21 Billion |
| 2023 | -4.84% | -6.66% | 0.68x | 1.07x | ₩-14.90 Billion |
| 2024 | -9.38% | -15.77% | 0.54x | 1.10x | ₩-18.10 Billion |
Industry Comparison
This section compares Curexo Inc's net assets metrics with peer companies in the Food & Drug Retailing industry.
Industry Context
- Industry: Food & Drug Retailing
- Average net assets among peers: $39,130,372,250
- Average return on equity (ROE) among peers: 13.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Curexo Inc (060280) | ₩94.30 Billion | -34.51% | 0.10x | $152.63 Million |
| Seouleaguer Co. Ltd (043710) | $39.13 Billion | 13.75% | 0.28x | $7.66 Million |